
ãã©ã³ã¹ãžã§ããã¯ã»ããã©ãšå¯çè«ã è¿ éãªããã»ã¯ããŒãã³ã°ã®ããã®çç©å µåšã·ã¹ãã
ã¢ãªã¢ãã»ã©ãå士è
2021幎11æ1æ¥
å èšäºã¯ãã¡ãã
ç§ãã¡ãé¥ã£ãŠãããã©ã³ã¹ãã¥ãŒããã¹ãã®ãã£ã¹ããã¢ã®æªå€¢ã¯ã
ããããCovid-19ãã¯ã¯ãã³ãã«å«ãŸãããã©Vulgarisãšå¯çè«ã®è¡æçãªçºèŠã«ãã£ãŠæ°ããªå±éãè¿ããŠããŸãã
ãã£ãªãŒã»ãããžå士ã2021幎9æ29æ¥ã®Stew Peter's Showã§ããã©ã®çºèŠãæããã«ããããã«ç¶ããŠã¶ã³ãã¬ã»ãã¿å士ãã¯ã¯ãã³æäžãåããæ£è ã®è¡æ¶²äžã«åŸ®çްãªèªå·±çµç¹åå»çããã€ã¹ãçºèŠãããšããé©ãã¹ãäºæ ãçºçããã®ã§ããèµ€è¡çã¯å±éºãªã»ã©å€åœ¢ãååºããŠãããè¡æ¶²å°éå»ãšããŠã®15幎éã§ããããŸã§èŠãããšããªããã®ã ãšåœŒå¥³ã¯èšãã

çŽ10æ¥åŸããã©ã³ã»ã¶ã¬ãŠã¹ããŒå士ã«ãã£ãŠããã¡ã€ã¶ãŒç€Ÿã®ãã€ã¢ã«ããããããïŒHydra VulgarisïŒãåå®ãããã圌ã¯ç§åŠãæ°ããã¬ãã«ã«åŒãäžããããã©ã®ååŠåæãè¡ãããã®çãç©ã®ååŠåæç©ãã¢ã«ãããŠã ãççŽ ãèçŽ ãå«ãã§ããããšãæããã«ããã®ã§ãããããã¯ããã©ã人éã«æ³šå ¥ãããåã«éºäŒåçµæããããŠããããšãæå³ãããå士ã¯ãŸããå°ç¶ã®äžã«å¯çè«ãããããšã確èªããã
補è¬ç ç©¶è ã®ãžã§ãŒã³ã»ã«ããŒå士ã¯ãã¶ã¬ãã¹ããŒå士ã®çºèŠã«ã€ããŠStew Peter's Showã§éèŠãªè§£èª¬ãããã°ã©ãã¡ã€ãããŒããšç±ã«ããããããšäŒç ç¶æ ã®ããã©ãåµããæŽ»æ§åããŠæé·ã墿®ããããšã匷調ããã
8æã®åãã«ããããŒãã»ã€ã³ã°å士ã«ãã£ãŠã4ã€ã®Covid-19ã®å°ç¶ããå¯çè«ãšãã®ä»ã®ææã確èªãããããžã§ãŒã³ã»ã«ããŒå士ãåã³Stew Petersã«å ãããã€ã³ã°å士ã®çºèŠã«ã€ããŠéèŠãªè§£èª¬ãè¡ã£ãã
調æ»å ±éèšè ã®ã©ã¢ã©Dã¯ãã€ã³ã°å士ãçºèŠããå¯çè«ã«ã€ããŠãããªãæ å ±ãæäŸãã10æã«æŽé²èšäºãæžããŠãããã
7æã«La Quinta Columnaã¯ãã¡ã€ã¶ãŒãã¢ãããã¢ã¹ãã©ãŒãã«ããžã§ã³ãœã³ïŒãžã§ã³ãœã³ã®4ã€ã®ãã¯ã¯ãã³ãã調æ»ãããã¡ã€ã¶ãŒ-ãã€ãªNTechã®è¡æž ããææ¯ãªããéå±åŸ®ç²åãç¹ã«ããé žåã°ã©ãã§ã³ã倧éã«çºèŠããããã«è質ããç²åLNPãšããªãããœãŒãã¯ã«ãŒãžãŒã®å¯çãçºèŠããŸããã
ãã¡ã€ã¶ãŒã®å éšåçºè ã§ããã«ã¬ã³ã»ãã³ã°ã¹ãã³ã¯7æã«Stew Peter's Showã«åºæŒããé žåã°ã©ãã§ã³ããã¹ãŠã®Covid-19è¡æž ã«å«ãŸããŠããããšããã¬ãŒã³ããŒã·ã§ã³ããŠæ©ãããé žåã°ã©ãã§ã³ã¯ç¹èš±åºé¡æžé¡ã«ã¯èšèŒãããŠãããã人äœã«æ¯ã§ããããšãç¥ãããŠãããããäŒæ¥ç§å¯ãšããŠæå³çã«é ãããŠããã®ã§ããã
ãããã®æãããçºèŠã®çµæãç§ã¯é žåã°ã©ãã§ã³ããç²åãšæ¯æ§ã«ã€ããŠç¬èªã«ç ç©¶ãããé žåã°ã©ãã§ã³ã¯Covid-19ã®å€§é殺æ®ã®ããã®ãã¯ã¿ãŒããšé¡ããèšäºãæžããŸãããç§ã¯ãé žåã°ã©ãã§ã³ã»ããç²åã人é¡ã«ããã«ç¡æ°ã®åœ¢ã§é£œåããŠããããæããã«ããã
ãŸããé žåã°ã©ãã§ã³ãäœå ãããããã¯ã¹ããããã®ãããã³ã«ã«ã€ããŠã¯ããã¡ãã®èšäºã§ã玹ä»ããŠããŸãã
Covid-19ã®çŸå®¹æ¶²ã«å«ãŸããŠããæåãèŠãã°ããã®æåãæããšã©ãŸãã«ã¯ååã§ããããä»ããã€ãªãã¯ãããžãŒè£œè¬æ¥çãäžè¬ã«å ¬è¡šããŠããªãæ¯ç©ããã®ä»ã®ææãããããšã¯æããã§ããã
ã«ã¬ã³ã»ãã³ã°ã¹ãã³ã¯ãã®æãããçºèŠãç¹èš±åºé¡æžé¡ãšé åæžã«ãã£ãŠè£ä»ãããŠããããã³ã°ã¹ãã³ã¯ããŽã¡ã¯ã·ã³ã¯ãåŸé ãªãã©ãããã©ãŒã ãžã®å ¥ãå£ã§ãããããããªããã¹ã³ã¢ã«åŸé ã§ãªããªããæœåšçã«åŠåã®ãã©ãããã©ãŒã ã§ããããšèª¬æããŠããã
ã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ããæŸæ£ãããŠããããã人ã
ã¯èªåãã¹ããŒãããã€ã¹ãçç©å
µåšã泚å°ãããŠããããšãç¥ããŸããã§ããã
ç¹èš±ã§ã¯ãæ¥çš®è
ããã¹ãŒããŒã¹ãã¬ãããŒããšãªããèŽåœçãªç
åäœãå¥åº·ãªäººã«ææãããããšããã¡ã€ã¶ãŒç€Ÿã«ãã£ãŠãã§ã«ç¥ãããŠããããšãæããã«ãããŠããã
ãããã®ã¯ã¯ãã³ã«ã¯AIã®èŠçŽ ããããã圌ãã¯ã¢ã¡ãªã«åœæ°ã人工ç¥èœã«çœ®ãæããããšã«å°œåããŠããããšãã³ã°ã¹ãã³ã¯èª¬æãããããã«åœŒå¥³ã¯ããéŠæž¯ã¯ä»ããã«ã§ãã¢ã¡ãªã«åœæ°ãããããã«çœ®ãæããæºåãã§ããŠããããšæãããã
ç¹èš±åºé¡æžé¡ã§ã¯ãã€ãªããã¯ã®ã¯ã¯ãã³æåã¯æããã«ãããŠããªããããç§ã¯ããã©ã»ãŽã¡ã«ã¬ãªã¹ãšå¯çè«ã«é¢ããç§åŠçãªæ»èªæžã¿ç ç©¶ã調æ»ãããªããããã人éã«æ³šå ¥ãããŠããã®ããç¹å®ã§ããªããã©ãã調ã¹å§ããã
æ©èœç²åŸ
ããã§æžããŠããããšã¯ãã¹ãŠãé廿°å幎ã«ãããç§åŠçãã¬ãŒã¯ã¹ã«ãŒãšæè¡éçºã«é¢ãããªãŒãã³ãœãŒã¹ã®æ»èªä»ãæç®ããã®èšŒæ ã«åºã¥ããŠããããã®èšäºã®äžã§ãªã³ã¯ãããŠããã
ãã®æ
å ±ãSFçã§ã¹ãªãªã³ã°ã«èããããããããªããããã®æè¡ã¯ãã§ã«é
åãããããããŠããéã«ãåã©ããã¡ã®éèã«æ³šå
¥ãããŠããã®ã§ãããç§ãããã§ãã£ãããã«ãããªããèªåã§ãã®ç ç©¶ãèªãããšãã§ããã
DNAã®ãã€ããªãã€ãŒãŒã·ã§ã³ã¯ã1980幎ã«ãããªã¢ã³C.ã·ãŒãã³ãèªå·±çµç¹åããæ§é ã®æ§ç¯ãéå§ããããšããå§ãŸã£ããããã©ã»ãã«ã¬ãªã¹ã®éºäŒåå°å ¥æè¡ã¯ããã®30幎ã®éã«éçºãããŸãããããã¯ãããçš®ããå¥ã®çš®ã«éºäŒåãçç©ãç§»æ€ããããšã§ãæ°ããã¯ããŒã³çš®ãäœãåºããšãããã®ã§ãã
ããã²ãã èšç»ã¯2,000幎ã«å§ãŸããŸãããããã²ãã ã®çµã¿ç«ãŠã§ã¯ãããã®éºäŒåãµã€ã¬ã³ã·ã³ã°ã«ããã©ã䜿çšãããŠãããã¡ãã»ã³ãžã£ãŒRNAïŒmRNAïŒãSPIONSïŒè¶ åžžç£æ§é žåéããç²åïŒãè¬å€ãååŠç©è³ªãå«ãDNAã³ãŒãã£ã³ã°è質ããç²åãéºäŒåçµã¿æãããã©ãå¯çè«ã¯ãã¹ãŠã人éã®å ç«ã·ã¹ãã ãè¿åããããªãã¬ãŒãã£ã³ã°ã·ã¹ãã ãã®äžéšãšãªã£ãŠããã®ã§ããã¢ãã«ãã®ããªãã¬ãŒãã£ã³ã°ã»ã·ã¹ãã ãã«ã€ããŠã®è©³çްã¯ãå瀟ã®ãŠã§ããµã€ãããã芧ããã ããŸãã
é žåã°ã©ãã§ã³ã·ãŒãã䜿ã£ãŠçްèèãåãéããããã°ã©ã å¯èœãªãããããããçŽ°èæ žã«å°éããŠãäžèŠãªéºäŒåã忢ããïŒéºäŒåãµã€ã¬ã³ã·ã³ã°ïŒã人工çãªéºäŒåé åãã³ãŒãåããããšãã§ããããã«ããŸãããã®ããã»ã¹ã¯ããã€ãªãããã³ã°ãšåŒã°ããŠããŸãã
ãããŒãã»ããŒãã£ã³å士ã«ãããšãé žåã°ã©ãã§ã³ã·ãŒãã¯ãæ¥çš®åŸ15å以å ã«äººäœã®ãããã现èèãåãéãããšãã§ããããã§ãã
DARPA ã¯ãç°çš®éã²ãã è§£æã®ããã®ã¿ã³ãã¯è³ª-ã²ãã é
åã¢ã©ã€ã³ã¡ã³ãã®éçºã«äžéšè³éãæäŸããŸããã
éºäŒåçµã¿æãããã©ãçšããæ©èœç²åŸã»åªå€±ç ç©¶ã¯ã
FauciãšNIHããè³éæäŸãåãã
äžåœã®æŠæŒ¢ç ç©¶æãšç±³åœãšäžåœã®å€§åŠã§éçºãããŸããããã®ç§åŠçç¥èŠã¯2013幎ã«çºè¡šãããŸããã
2017幎8æ26æ¥ãã28æ¥ã«ãããŠãäžåœã»å京ã§ã第6åDNAãããã¯ãããžãŒåœéã¯ãŒã¯ã·ã§ããããéå¬ãããèªå·±çµç¹åDNAããæ§é ã®å¿çšäºäŸã玹ä»ãããŸããã
https://pubs.acs.org/doi/full/10.1021/acsami.9b04482#
ãã¡ã©ã¹ãã€ã¯ã¿ã³ãã¯è³ª
ã¿ããªã話é¡ã«ããŠããCovid-19 vaxxinesã®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãã¯ãLentivirusãšåŒã°ãããã®ã§ããã¬ã³ããŠã€ã«ã¹ã¯ãHIV1ã3åãSRV-1/AIDSãMERSãSARSãçµã¿åããããã®ã§ããããããã¯å€§é殺æ®ãè¡ããã¡ãŠãã®ãããã§ããããŸã§ã«éçºãããæãèŽåœçãªãæ©èœç²åŸåãçç©å µåšãªã®ã§ããã
ã¹ã¿ã³ãã©ãŒã倧åŠã®ç ç©¶ã«ãããšãhttps://ehs.stanford.edu/reference/lentivirus-fact-sheet
ã¬ã³ããŠã€ã«ã¹ã¯ãããã«é·ãæœäŒæéãç¹åŸŽãšããæ
¢æ§çã§èŽåœçãªç
æ°ãåŒãèµ·ããã¬ãããŠã€ã«ã¹å±ãã§ããããšãæããã«ãªã£ããé·æéã®éºäŒåçºçŸãå¯èœã«ãããã®ã§ãããæãããç¥ãããŠããLentivirusã¯ãAIDSã®åå ãšãªãããå
ç«äžå
šçã®ç
åäœã§ãããããããCovid-19æ¥çš®åŸã«èªå·±å
ç«ãç¥çµå€æ§ã®äœäžãèŠãããçç±ã§ããããã¯PRIONãšåŒã°ããèªå°ç¶æ
ã§ãã
ã¬ã³ããŠã€ã«ã¹ãã¡ã©ã«ã¯ãã«ã®mRNAã¯ã䟵襲çãªæé ã§ãã现èã®DNAã«æ¿å
¥ããããã®çްèã®ã²ãã ãæ°žä¹
ã«å€åãããã宿䞻现èã®çްè質å
ã«å
¥ããšãè質ã§ã³ãŒãã£ã³ã°ãããããããããã¬ã³ããŠã€ã«ã¹ã«å«ãŸããé転åé
µçŽ ãåã蟌ã¿ãéåžžã®ãã¿ãŒã³ãšã¯éã«ãmRNAã®ã²ãã ããDNAãçæãããããã¬ãããšãªãã
ãã€ãã©2.0 ã²ãã ã¢ã»ã³ããª
ããã©ã¯çš®ãè¶
ããã²ããã¯ã¹ã«å©çšãããŠãããããŒã«å€§åŠã®ç 究宀ã§éºäŒåçµã¿æããè¡ãããã©ã³ã¹ãžã§ããã¯ã»ã¯ããŒãã«ã»ããã©ç³»çµ±ãçç£ããŠããã
2006幎以æ¥ãäœåãã®èããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ããã200è¿ãã®ãã©ã³ã¹ãžã§ããã¯ç³»çµ±ãããã©éºäŒåçµã¿æãæœèšã«ç¢ºç«ãããŠããŸãã
ããã©ãçšãã圢æ
圢æãšå¹¹çްèå¶åŸ¡ã¯ãããã®ç¥çµçç©åŠçæ©èœã®åŠç¿ãšin vivoã§ã®çްèã®è¿œè·¡ã®ããã«éçºãããŸããã
éºäŒåçµæãããã©ã«ããã圢æ
圢æïŒçµç¹ã现èã®æé·ïŒäžã®åã
ã®å¹¹çްèãin vivoã§è¿œè·¡ããããšãã§ããŸãã
ãã©ã³ã¹ãžã§ããã¯ããã©æ ªã¯ããã¯ããªã¢ã«èŠãããèªå·±è€è£œDNAããã®ãã©ã¹ããDNAãèã«ãã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ããããšã«ãã£ãŠäœè£œããããããã¯ãéºäŒç©è³ªïŒDNAïŒã®æ°žä¹
çãªäŒéå¯èœãªå€åã§ããããã®çµæãã¿ã³ãã¯è³ªã®çç£ãæžå°ããã
ãã®2ã€ã®çš®ã®èåã¯ããã©ã³ã¹ãã§ã¯ã·ã§ã³ãšãããã¯ããŒã³åãããã»ã¹ã§ããããã©ã³ã¹ãžã§ããã¯ã»ããã©ã»ããªãã®æ°ããäžä»£ã¯ããã¡ã©éºäŒåã®çºçŸããã®åå«ã«åçŸãç¶ããã
ãããã®éºäŒåçµã¿æãããã©ãããã¹ã¯ãä»ãéºäŒåã³ãŒãåããããã¯ã¿ãŒã§ããããããžã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãç®çãšããŠãããã°ã©ã ãããæ§ã
ãªåæã²ãã é
åãšmRNAïŒã¡ãã»ã³ãžã£ãŒRNAïŒãæèŒããŠããŸãã
ããã®äœå
ã«å
¥ããšããããã®éºäŒåçµã¿æãããã©ãããã¯ãããã®ç¥å
ã®åè·¯ãåé
ç·ããå¶åŸ¡ãã圹å²ãæããã®ã§ããã
BLASTé åæè¡ã¯ãæ°ããDNAé åã®äœæãçš®éã®é¡äŒŒããéºäŒåé åã®çºèŠã«å©çšããã転åãç®çãšããåçš®ã»ç°çš®ã®éºäŒåã¹ãã©ã€ã·ã³ã°ã®ããã®ã¢ã©ã€ã¡ã³ãæ©èœãæãããŠããã
ã¿ã³ãã¯è³ªã¯éºäŒåçºçŸãå¶åŸ¡ããããã®æè¡ã¯ãéºäŒæ å ±ãä¿åããæ žãååŠãšãã«ã®ãŒãçç£ããããã³ã³ããªã¢ãã¿ã³ãã¯è³ªãçµã¿ç«ãŠããªããœãŒã ãšãã现èå°åšå®ã察象ã«ãmRNAãçšããŠããã³ã³ããªã¢ã®é åãäœãã
2017幎ã®ãã€ãããã®æ©èœç²åŸç ç©¶ãããžã§ã¯ãã§ã¯ãRNAæœåºãšå®éçé転å-ããªã¡ã©ãŒãŒé£éåå¿ããŸãã¯ãªããŒã¹ãžã§ããã£ã¯ã¹ããããã©ãšCRISPR/Cas9ãçšããŠãéºäŒåã®ããã¯ã¢ãŠããšããã¯ããŠã³ã«äœ¿çšãããŠããããšãå®èšŒããŠããŸãã
Covid-19ãªãã¬ãŒãã£ã³ã°ã·ã¹ãã ã®éºäŒåçµæãããã©ç³»çµ±ã¯ããŸããã¡ã©éºäŒåé åïŒã¬ã³ããŠã€ã«ã¹ïŒã§ã³ãŒãåãããCRISPR-Cas9æè¡ãšãšã¬ã¯ãããã¬ãŒã·ã§ã³æ³ã«ãããã现èã«ã³ãŒãåãããŠããã
éè²ã®ããã°ã©ã å¯èœãªããããããã«åãä»ãããã黿¥µãããã®çްèããã©ã³ã¹ãã§ã¯ãããããªãã®çæ¥ã®ç¥ããäžããããéºäŒåé åãæ²é»ãããããªãã®çްèããã¡ã©ã¹ãã€ã¯èçœïŒã¬ã³ããŠã€ã«ã¹ïŒã®åæéºäŒåé åãæ°žä¹ ã«åçããããã«ã³ãŒãåããŸãããã£ãšç°¡åã«èšãã°ãããªãã®çްèã¯ãããªããæ³šå°ããããã¡ã©ç åäœã®æ°ããéºäŒåé åã§ãäœåºŠãäœåºŠãèªå·±è€è£œãç¶ããã®ã§ããåããã¡ã©ç åäœã¯ããã€ãªãããªã¹ãã®ã¢ã³ãœããŒã»ãã¡ãŠããè³éãæäŸããäžåœã®æŠæŒ¢ã§éçºããããã®ã§ããã
ããã©ãããã«ç§»æ€ããããã«ãã¡ã©åŒ·åãããŠããèŽåœçãªãã¯ããªã¢ã®äžã€ã¯å€§è žèã§ãããããã®ææçã®çŽ36ïŒ ãåŒãèµ·ãããŠããã
å¯çè«
å¯çè«ããŸãã现èããã©ã³ã¹ãã§ã¯ãããDNAçµåãããã§ã®éºäŒåé
åæ±ºå®ã®ããã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãã¯ã¿ãŒãšããŠäœ¿çšãããŠããã
å¯çè«ã¯è¬å€ãåé¿ããå
ç«ç³»ããéããéºäŒåãå¶åŸ¡ããããšãã§ããŸãã
ã¹ã¿ã³ãã©ãŒã倧åŠã§éçºããããããã©ãªã¢ã²ãã ãããžã§ã¯ãã§ã¯ãCRISPRæè¡ãšå¯çè«ã®å éšã§æ¥éã«è€è£œã§ãã现èãã©ã¹ãããçšããããã圌ãã¯ãå¯çè«ã«çްèãã©ã¹ãããå°å ¥ããäžé£ã®éºäŒåã³ãŒãåååãç Žå£ããããã®ç ç©¶ã§ã¯ããã©ãªã¢åè«ã«ã«ã·ãã§ã©ãŒãŒãå°å ¥ããããã§ã®éºäŒåã¿ãŒã²ãã£ã³ã°ãšãã©ã³ã¹ãžãŒã³çºçŸã«å©çšããããšãç®çãšããŠããã
T. gondiiãP. falciparumãªã©ã®å¯çè«ããã©ã³ã¹ãã§ã¯ã·ã§ã³ç ç©¶ã«äœ¿çšããããããã§éèŠãªã®ã¯ãP. falciparumãããDd2ãšããã¯ãããã³èæ§ã®ãã©ã³ã¹ãžã§ããã¯å¯çè«æ ªãèšèšããããšã§ããã
ã«ã·ãã§ã©ãŒãŒïŒLUCIFERASE)
ããã©ã®ããªãŒãã¯ãŸããã«ã·ãã§ã©ãŒãŒãšåŒã°ããéå°çºçŸãããã¡ã©ã¿ã³ãã¯è³ªïŒãã¿ã«ç±æ¥ã®ç·è²èå ã¿ã³ãã¯è³ªïŒã§ã³ãŒãåãããŠããŸãããã©ã³ã¹ãžã§ããã¯ã»ããã©ã«ã¯ãã«ã·ãã§ã©ãŒãŒRNAããªã¬ãŒãæèŒãããŠãããããªãã®çްèãã³ãŒãåãããã现èã®éºäŒåãæ²é»ãããããšãã§ããŸãã
Holsteinç 究宀ã¯ãHyWnt3ããã¢ãŒã¿ãŒã«å¯ŸããHySp5ã®æå¶æŽ»æ§ããããHEK293T现èã§ã«ã·ãã§ã©ãŒãŒã¬ããŒã¿ãŒã¢ãã»ã€ãè¡ã£ãŠDNAçµåã調ã¹ãããã®çµç¹ã«äŸµå ¥ããŠããã©ãããã«ç§»æ€ããŠã¿ãã
ãã©ã³ã¹ãžã§ããã¯ãªããã©ãšå¯çè«ã¯ãã©ã³ã¹ãã§ã¯ã·ã§ã³ã®éã«è€è£œãããããã«èåããããããã¯äžç®çްèç³»ã®ããããã«å°å ¥éºäŒåïŒã«ã·ãã§ã©ãŒãŒãšã¬ã³ããŠã€ã«ã¹ïŒãšå ±ã«çµã¿èŸŒãŸããããã®å®¿äž»ã«ååãããããã©ãããã«ç§»æ€ããããšã¯ãèªå°ãããããã©ããç§»æ€çããšããŠçšãããã¢ãã©ã¹ãç§»æ€ãšåŒã°ããŠããŸãã
äžç®çްèã¯ã现èã·ã°ãã«äŒéãæ ã幹现èç³»ã§ãããéºäŒåçµã¿æãããã©ã®ã¬ããŒã¿ãŒéºäŒåã¯ãç¥çµãããã¯ãŒã¯ã«ããããã¥ãŒãã³ã®ããã«ãããã®äœå ã§äºãã«çްèã·ã°ãã«ãäŒéãåã£ãŠããããã©ã³ã¹ãžã§ããã¯Hydraã®çްèã·ã°ãã«ã¯ãHydraã®æŽ»æ§åå åãçºçŸãããã©ã¹ããïŒHySp5-2992ïŒLucïŒã«å¯Ÿããã¢ããã¬ã®ã¥ã¬ãŒã·ã§ã³ïŒçްèå¿çïŒã«ãããããã®éºäŒåã®å€ç°ã«ãã£ãŠèªå°ãããã«ããã³ã·ã°ãã«ãšåŒã°ããããã»ã¹ã§ããã®çްèã·ã°ãã«ãšåæãããããã«ãªãïŒãããããã©ã³ã¹ãã§ã¯ã·ã§ã³ã§ããã
ãã©ã³ã¹ãžã§ããã¯ããã©ãšå¯çè«ã¯ãé µçŽ ã空éçã«çµç¹åããŠããã°ã©ã å¯èœãªé žåéå é µçŽ ã«ã¹ã±ãŒãçµè·¯ãäœããããã®äºæž¬å¯èœãªé»æ°ååŠä¿¡å·ã®çºçãå€åãããããšã«ãããããã«æ°ãã黿°ååŠä¿¡å·ãçºçãããããã«èªå°ãããæ°ãã«ç¢ºç«ãããåæéºäŒåé åã¯ããã©ã³ã¹ãžã§ããã¯ããã©ãå¯çè«ããããŠæ°ãã«ãã€ããªãã€ãºããããã®éã§å ±æãããããã«ãªã£ãã
å®éããã€ãªããã¯ã®ãã¡ã©OSã¯ãå
å æ§ã®ç¥çµå¹¹çްèãåæåããããšã«ãã£ãŠãããã®æ°ããç¥çµãããã¯ãŒã¯ãšäººå·¥è³ã確ç«ãããè³ã€ã³ãã©ã³ãã¯èšæ¶ãæ¶ããæ°ãã人工çãªèšæ¶ãç§»æ€ããããšãã§ããã
äžæ¹ãé
žåã°ã©ãã§ã³ã¯ãããªãã®è³ã®ãããããèããããšãã§ããã
ã«ãªãã©ã«ãã¢å€§åŠããŒãã¹æ ¡ãšã©ã€ã¹å€§åŠã®ç§åŠè ããŒã ããç¥çµåè·¯ãšäººéã®è¡åãå¶åŸ¡ããããã«ãããã©å°åžžæ§ç¥çµãšäººéã®ç¥çµç³»ãæäœããŠãäžããæ°ããè³ãäœããããšã7æã«èªæ ¢ãã«è©±ããŠããããã®æè¡ã¯ãããã¥ãŒãã³ã»ãã¬ã€ã³ã»ãããžã§ã¯ãããéããŠéå»10幎éã«éçºããããã®ã§ããã
欧å·é£åã®15åãŠãŒãã®ãã°ã©ãã§ã³ã»ãã©ãã°ã·ããã»ãããžã§ã¯ããã§ã¯ããæªæ¥ã®ãã¬ã€ã³ã»ã³ã³ãã¥ãŒã¿ãŒã»ã€ã³ã¿ãŒãã§ãŒã¹ãçšã«ã°ã©ãã§ã³ãçšããã€ã³ãã©ã³ããéçºãããã圌ããèšããã€ã³ãã©ã³ããã«ã¯ãéºäŒåçµã¿æãã®ããã©ãå«ãŸããŠããã®ã ããããšæããããåŸãªãã
ã°ã©ãã§ã³ã»ã€ã³ãã©ã³ãã¯ãè³ã®é»æ°ç掻åãæ¥µããŠäœãåšæ³¢æ°ã§ããã€åºãç¯å²ã«ããã£ãŠèšé²ããããšãã§ããã0.1 Hz以äžã«èŠãããè±å¯ãªæ å ±ãè§£ãæŸã€ãããšãã§ãããšããã
ãã·ã¢ã®2045幎ãšããæ§æ³ã§ã¯ãç¥çµã€ã³ã¿ãŒãã§ãŒã¹ãã人éãã®ãã®ã®æ¹åãã«äœ¿ãããšããŠãããããã¯ãå šäººé¡ã®ã¯ããŒã³ãäœãããšããåªçåŠè ããå人éçãªèãæ¹ãããŠããããšã瀺ããŠããã
ãŸããèå ïŒã«ã·ãã§ã©ãŒãŒïŒããã©ã¯ãå€éšããé»çããããã©ãã ãã®é»å§ã«èãããããããã¹ããããããã¯ããçºè²äžã®çµç¹ã§çްèå æåãååé ããå®éšææ®µãšããŠé»çãå°æ¥å©çšãããããããããã§ãã£ããããã¯ãããã©ã5Gåšæ³¢æ°ã«èãããããã©ããããã¹ãããããã ãšæãããŸãã
ãªãã¬ãŒãã£ã³ã°ã·ã¹ãã
ããã©ãšå¯çè«ã¯ãã¬ããŒã¿ãŒã·ã¹ãã ãšããŠã®åœ¹å²ãæãããŠãããã«ã·ãã§ã©ãŒãŒã¯éè²ãã玫å€åã®å ãåœãŠããšæããç·è²ã®èå ã瀺ãããŽã¡ã¯ã·ã³ã°ãå€éšãããã¬ãŒã¹ããããšãå¯èœã§ããèå³ã®ããéºäŒåã¯ããã©ã³ã¹ã¬ã®ã¥ã¬ãŒã·ã§ã³ãšåŒã°ããæ¹æ³ã§ãç¹èš±æš©è ã®ææã§æã ãªãã«ãããããªã³ã«ãããããããšãã§ããã
ã€ãŸããããªãã¯24æé365æ¥ãå€éšãã远跡ãããã ãã§ãªããå€éšããã³ã³ãããŒã«ãããããšã«ãªãã®ã§ããç¹èš±æš©è ã¯ãçæ žçç©ã²ãã ã»ã¢ãããŒã·ã§ã³ã»ãã€ãã©ã€ã³ãšããéºäŒåçµã¿æãããã®ããã®å€éšããŒã¿ããŒã¹ãéããŠãããªãã®éºäŒåã³ãŒããã¢ããã¬ã®ã¥ã¬ãŒããããããŠã³ã¬ã®ã¥ã¬ãŒããããããããšãã§ããããã«ãªãã®ã§ãã
ã¹ã¿ãŒãªã³ã¯è¡æãããã¯ãŒã¯ã®ã粟å¯è¿œè·¡å®å®ã·ã¹ãã ãã¯ãé²è¡ãšé¢ä¿ããããšãæãã§ãããïŒå¿é ããªãã§ãã ãããããªãã®ããŒããã³ã¬ãã«ã解決ããŠãããéããããªãã¯äœãææããªãã§ãã幞ãããªã®ã§ãã
ADDGene瀟ã¯ããããžã®éºäŒåå°å ¥çšãã¯ã¿ãŒãšããŠäœ¿çšããããã®ãããŸããŸãªCRISPRå¯çè«ã販売ããŠããããããã¯ãã¯ã¯ãã³ãã§ã¯ãªããéºäŒåããã¯ã¢ãŠãïŒãµã€ã¬ã³ã·ã³ã°ïŒã人工çãªéºäŒåé åæ±ºå®ïŒã³ãŒãã£ã³ã°ïŒãããå éšã®ãã©ã³ã¹ãã§ã¯ã¿ã³ãã®ç£èŠïŒãã¬ãŒã¹ïŒãªã©ãéããŠããããæ¥éã«ã¯ããŒãã³ã°ïŒåœŒãã®èšèïŒããããã®æŠåšã·ã¹ãã ïŒç§ã®èšèïŒãªã®ã§ããã
ProSplignã¯ãäžæ¬éRNAããã³ãã¬ãŒãã«ãé転åé µçŽ ãè§ŠåªãšããŠããDNAã容æã«åæã§ãããäžççãªã¿ã³ãã¯è³ª-ã²ãã ã¢ã©ã€ã¡ã³ãããŒã«ã§ãã
ADDGeneã¯ããã©ã³ã¹ãžã§ããã¯ããã©ãçšãããããžã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³ã®ããã®Lentiviral Envelopeãšããã±ãŒãžã³ã°ãã©ã¹ãããæäŸããŠããŸãããŸããããã©ã«æ°ããç¥çµåè·¯ãæ§ç¯ããããã«ãããã©å°åžžçãçšãããNon-overlapping NEURAL NETWORKSãïŒå瀟ã®èšèïŒãæäŸããŠããããã®æè¡ã¯çŸåšãCoivd-19 Quackccineããã°ã©ã ãéããŠããã«å±éãããŠããã
ãã£ãªãŒã»ãããžå士ããã·ãã¥ãŒã»ããŒã¿ãŒã®ã·ã§ãŒã§ã®ææ°ã®ã€ã³ã¿ãã¥ãŒã§ããŽã¡ã¯ã·ã³ã»ãªãã¬ãŒãã£ã³ã°ã·ã¹ãã ã人éã®äžã§äººå·¥ç¥çµåè·¯ç¶²ãæ§ç¯ããŠããããšãæãããŠããã
ADDGene瀟ã¯ãéºäŒåçºçŸããªã³ïŒãªãããããã©ãµã€ã¯ãªã³ã»ãªãã·ã¹ãã ãæäŸããŠããããtetRãšHSVïŒåçŽãã«ãã¹ãŠã€ã«ã¹ïŒç±æ¥ã®å¿ é è»¢åæŽ»æ§åãã¡ã€ã³ã§ããVP16ïŒããªãªã³ã¿ã³ãã¯16ïŒã®Cæ«ç«¯ãã¡ã€ã³ãèåããããã§ã®ãéºäŒåçºçŸãæãããããã«äœ¿çšãããŠãããããã¯ããã¡ã©å€§è žèãšLentivirusã䜿çšããŠããŸãã
Hydraã²ãã ã¢ã»ã³ããªã§ã¯ãIlluminaãšåŒã°ããNano DNAããããæäŸããŠããŸããã€ã«ãã瀟ã¯ã2007幎ã«ããã²ãã ã®ã·ãŒã±ã³ã¹ã®ã³ã¹ãã100äžãã«ãã1,000ãã«ã«åŒãäžããæ¹æ³ãèãåºããŸããã
ã«ã·ãã§ã©ãŒãŒãæ³šå ¥ããã³ã³ãã¥ãŒã¿ã§æšçéºäŒåãã³ãŒãåããåŸãå ¬éãããŠããã®ã£ã©ã¯ã·ãŒãµãŒããŒãéããŠããã«ãããã³ã°ãããçºçŸå·®ç°è§£æããè¡ããã¿ã³ãã¯è³ªãã¿ãŒã²ããã«ããã¢ããã¬ã®ã¥ã¬ãŒã·ã§ã³ãããŠã³ã¬ã®ã¥ã¬ãŒã·ã§ã³ãè¡ãããšãã§ããã
ãŸããVector Biolabs瀟ã§ã¯ãããsp5 shRNAãµã€ã¬ã³ã·ã³ã°çšã®ã¢ãããŠã€ã«ã¹ã販売ããŠãããç¹å®ã®éºäŒåã®çºçŸãããã¯ããŠã³ããïŒéºäŒåãµã€ã¬ã³ã·ã³ã°ïŒããã®ããã¯ã¢ãŠããã¯ã¿ãŒã·ã¹ãã ïŒã¢ãããŠã€ã«ã¹ïŒãããã¯ã¿ãŒãã«ããŒç€Ÿãããªã³ã©ã€ã³è²©å£²ãããŠããã人工çãªã²ãã é åãäœæããç°ãªãçç©çš®ã®ã²ãã ãèåãããããšãã§ããŸãã
HydraAtlasã®ããŒã ããŒãžã§ãããã®DNAé åãäºçŽæ³šæããããšãã§ããŸãã
Genome Data Viewer (GDV) ã¯ãããã²ãã ãããžã§ã¯ãã§é åæ±ºå®ããããäž»ã«å®æããããã¯ããŒã³ãããããçšã®ã²ãã ã¢ã»ã³ããªïŒDNAé åïŒãéžæããããšãã§ããŸãã
VIGENE瀟ã§ã¯ãéºäŒåãµã€ã¬ã³ã·ã³ã°å®éšã®ããã«ãè€æ°ã®shRNAã¯ããŒãã³ã°ãªãã·ã§ã³ãæäŸããŠããŸãããã©ã¹ãããã¢ãããŠã€ã«ã¹ïŒAAVïŒãã¬ã³ããŠã€ã«ã¹ã®ããã±ãŒãžã³ã°ãè¡ããç®çã®éºäŒåãå°ãªããšã70ïŒ ããã¯ããŠã³ããããšãä¿èšŒããŠããŸããããã²ãã ãæšçãšãã27,000以äžã®shRNAãã©ã¹ããã»ããã®ã«ã¿ãã°ãæããŠããŸãã
ãã®è¡šã¯ã第2äžä»£ããã³ç¬¬3äžä»£ã®ã¬ã³ããŠã€ã«ã¹æè¡ã§äœ¿çšã§ããäžè¬çãªã¬ã³ããŠã€ã«ã¹ã®ãšã³ãããŒãããã³ããã±ãŒãžã³ã°ãã©ã¹ããã®äžèЧã§ãã
ADDGeneã®ã¬ã³ããŠã€ã«ã¹ã²ãã ã¯ãCRISPR gRNAãçšããŠæææã«æšç现èãžééãããŸããç ç©¶è ãïŒãããã¯ç¹èš±æš©è ã倧æè£œè¬äŒç€ŸïŒãç¹å®ã®æšç现èã«ééããããéºäŒç©è³ªããã¬ã³ããŠã€ã«ã¹ã²ãã ãã©ã®ããã«ã³ãŒãããŠãããã説æããŠããŸããã²ãã ã¯ããã©ã³ã¹ãã¡ãŒãã©ã¹ããããšåŒã°ãããã©ã¹ããã«ãã£ãŠã³ãŒããããŠããããã®ãã©ã¹ããã¯ãããŸããŸãªéºäŒåç£ç©ãã³ãŒãããããã«æ¹å€ããããšãã§ããã
ADDGene瀟ã¯ãå瀟ã®DNAæšçé µçŽ ããæšçãšããRNAãDNAãåé€ããããæ¿å ¥ãããããã®ä»ã®æ¹æ³ã§æ¹å€ããããšãéåžžã«å€ãããšãèªããŠããã
ã¬ã³ããŠã£ã«ã¹ãã©ã¹ããã¯ADDGene瀟ããæ³šæããããšãã§ããŸãã
è¡åå¶åŸ¡
ãã¯ã¿ãŒã»ãã€ãªã©ãã§ã¯ãHuman SP5ã®ããã¯ã¢ãŠãïŒéºäŒåãµã€ã¬ã³ã·ã³ã°ïŒã®ããã®shRNAãçºçŸããã¢ãããŠã€ã«ã¹ïŒAAVïŒãæäŸããŠããŸããåç©å®éšã®éã«ãã®æè¡ãéçºãããšããã4é±éåŸã«ç€ŸäŒçèªèã空éåŠç¿ãèšæ¶åãæãªãããŸããã
ãŸããã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒãšè¬å€ãçšããé転åé µçŽ ããªã¡ã©ãŒãŒé£éåå¿ïŒRT-PCRïŒã«ããåç©å®éšã§ã¯ãè³ã®ç·æ¡äœãæšçãšããŠãã³ãã³ãã³ç ãèªçºãã100åã®ç¥çµå€æ§ãšéåè¡åé害ãåŒãèµ·ããããšã«æåããŸããã
çæ®ã»ç¹æ®èœå
ãã©ã³ã¹ãžã§ããã¯ã»ããã©ã¯ãç·æ§ã®ç²Ÿå·£ã女æ§ã®åµå·£ã«ããè现èãç¥çµçްèãäž»ãªã¿ãŒã²ãããšããŠéºäŒåãµã€ã¬ã³ã·ã³ã°ãèªå°ããããã«äœ¿çšãããŠãããããããæ¥çš®åŸã«ç¥çµå€æ§ïŒããªãªã³ïŒãèŠãããçç±ã§ããããŸããããžã£ãããæ³šå°ããåŠå©Šã®82ïŒ ãèªç¶æµç£ããŠããã®ããã®ããã§ããã
å粟ããããŠã¹ã®å现èèã®åæ žã«å€æ¥DNAããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ããŠãåŸä»£ã®éºäŒåçºçŸãå¶åŸ¡ããããšãã2008幎ããã宿ããŠããã
éºäŒåçºçŸãå¶åŸ¡ããã¿ã³ãã¯è³ªããã®éºäŒåã¯ãæè²äœ2q31.1ã«ããGC-boxããã¢ãŒã¿ãŒèŠçŽ ã«çµåããã¿ã³ãã¯è³ªãã³ãŒãããŠãããçºçäžã®èã§èµ·ããè€éãªè»¢åã®å€åã調æŽãã圹å²ãæãããšèããããŠããŸãã
Wnt-3ã¯ãããã§ã¯WNT3éºäŒåã«ãã£ãŠã³ãŒããããã¿ã³ãã¯è³ªã§ããããããã®ã¿ã³ãã¯è³ªã¯ãçºããããèçºçäžã®çްèã®éåœããã¿ãŒãã³ã°ã®å¶åŸ¡ãªã©ãããã€ãã®çºçããã»ã¹ã«é¢äžããŠããããšã瀺åãããŠããã
ããã§ç§ãèšãããã®ã¯ããªãã¬ãŒãã£ã³ã°ã·ã¹ãã ã¯DNAçµåãããŠã³ã¬ã®ã¥ã¬ãŒã·ã§ã³ããããŠãã©ã³ã¹ãžã§ããã¯ããã©ã䜿ã£ãŠãããã®èãè现èãã¿ãŒã²ããã«ããŠãWnt/βã«ããã³ä¿¡å·çµè·¯ãžã®çµåéºäŒåããçºççå€åãå°ããšããããšã ã
ãã®æå³ããåããã«ãªããŸããïŒéºäŒåæäœãããã¯ããŒã³åããããã€ããªããåãããŠããã®ã¯ã¯ã¯ãã³æ¥çš®è ã ãã§ã¯ãªãããã®åå«ãåããªã®ã§ããããã¡ãããæ¥çš®åŸãç¹æ®ãå¯èœã§ããã°ã®è©±ã§ãããã»ãšãã©ã®äººã¯äžåŠæè¡ãåãããã®èµ€ã¡ããã¯å èãããããã ãã§ãããããã¯äººéã®ã¯ããŒã³å®éšã§ãããé§é€ã§ãããã®ã ã
ã¬ãããŠã€ã«ã¹ã®å°å ¥éºäŒåïŒã¬ã³ããŠã€ã«ã¹ãšã«ã·ãã§ã©ãŒãŒïŒã®ãã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ã¯ã²ãã ã«ã©ã³ãã ã«çµã¿èŸŒãŸããã¯ã¯ãã³æ¥çš®è ãšãã®ãã€ããªããåå«ã«ç倧ãªãªã¹ã¯ããããããããã¯ã1ã€ãŸãã¯ãã以äžã®å¡©åºå¯Ÿã®è¿œå ã«ãã£ãŠãDNAã«å¥åŠã§äºæž¬äžå¯èœãªçªç¶å€ç°ãèµ·ããå¯èœæ§ããããããããŸãã«ãç°åžžãªçªç¶å€ç°ãèŠãããçç±ã§ãããå»åž«ããã£ãŒã³ãšã€ãžã£ãŒããããã©ã®ãããªè§Šæãæã€è¡æ ãé€å»ããŠããçç±ãªã®ã ã

ããã§ãçŽåŸã§ããªãæ¹ã¯ã2021幎10æ2æ¥ã«éå¬ããã第78åç±³åœå»åž«å€ç§å»äŒå¹Žæ¬¡ç·äŒã§ãããŒã¿ãŒã»ããã«ã©å士ããã®ãã€ãªãã¯ãããžãŒãšãã¡ã©ã¹ãã€ã¯èçœè³ªãã©ã®ããã«ãã现èã«ã³ãŒãåãããŠãããã説æããŠããŸãã®ã§ããã²èããŠãã ããããŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒ
ãããã¯èŽåœçãªã¿ã³ãã¯è³ªã§ãããšããã«ããŒå士ã¯èª¬æããããã¯ã¯ãã³ã泚å°ããŠã人äœã«èŽæ»æ§ã®ã¿ã³ãã¯è³ªãäœããããšããã®ã¯ãå»åŠã®äžçã§ãåããŠã®ããšã§ããã
ã³ããã19ã®è¡æž ã¯ã衚é¢äžã¯éæãªæ¶²äœã«ããèŠããªãããé¡åŸ®é¡ã§èŠããšãã³ã³ãã¥ãŒã¿ã»ã€ã³ã¿ãŒãã§ãŒã¹ã»ãªãã¬ãŒãã£ã³ã°ã»ã·ã¹ãã ã®å€ãã®æ§æèŠçŽ ããã¹ãŠç®ã«èŠããããã«èŠããã
ãã¡ã€ãã«ããŒã
ãããã¯ã¹ãããã³ã«ãšãžã£ãããè¡æ ã«ã€ãªããè¡æ¶²ååºã«ã¹ã±ãŒããç Žå£ããããŸãã¯äŒéã®æªåœ±é¿ããããªããä¿è·ãããããã³ã«ã«ã€ããŠã®è©³çްæ å ±ããåžæã®å Žåã¯ãç§ã«çŽæ¥é£çµ¡ããŠãã ããïŒ metanutrients@mailfence.com
åèåç»
TEDæ¥æ¬èª - ãžã§ããã¡ãŒã»ã«ãŒã³: ïŒã€ã®çç©çš®å šäœãæ°žä¹ ã«å€ããŠããŸãéºäŒåç·šéæè¡(CRISPRéºäŒåãã©ã€ã)
https://digitalcast.jp/v/24594/
2   The Battle For Humanityãã®äžã§ããã£ãªãŒã»ããã€ãŒå士㯠ãããã®æ³šå°ã人éã®DNAãæ°žä¹ ã«å€ããŠããŸããæ²æšãªçµæãæãå¯èœæ§ããããšèŠåããŠããŸãã
3 ã¯ã¯ãã³æ¥çš®è
åã³ãã®åå«ã¯äººéã§ã¯ãªã ã ã¢ãªã€ãã»ã©ãå»åž«
4  ãããšã«ã»ãã¬ã»å士ã人é¡ã®éºäŒåããŒã«ããæ±æãããŠããã
5  ã¯ã¯ãã³ãšããåã®çç©å
µåš
6   ãã©ã³ã·ã¹ã»ãã€ã«å士ãçç©å
µåšããå¯Ÿçæ³ã®ç¬¬äžäººè
ãèªãïŒã
âéšããðå°ã€äººã«ã¯ã©ããªçµæ«ãåŸ
ã¡åããŠããã®ãïŒ
âæ¬¡ã®ãã³ããæ¢ã«çšææžïŒ
âWHOãã³ãããã¯æ¡çŽã®çœ ã¯ïŒ
âçŠæ¢ãããã®ã«ðºðžè»ç£è€åäœã«ããéçºãããçç©å
µåšã䜿çšïŒ
âãã¥ã«ã³ãã«ã¯æ³ã人é¡ã«å¯Ÿãã眪ã«åœããïŒ
åèèšäº
1  DARPAã®ãã€ããã²ã«ãšããã©ã®å¯çè«ã³ãã¯ã·ã§ã³ã
ããã¯DARPAã®æŠåšåæè«ããã°ã©ã ããããŠPALSããã°ã©ã ããå§ãŸãã2016幎ã«ãã€ããã²ã«ã®ãã©ãããã©ãŒã ãå©çšãããçç©ã«ã€ã³ã¹ãã€ã¢ãããå¯çè«ã«å€èº«ããã®ã§ããã
2  ãã¡ã¬ãã ! éºäŒåçµã¿æãå¯çè«ã¯mRNAãã¯ã¿ãŒã§ããã
æªã®æ¯é
è
ã¯ããšã¢ããŸã«åããçåæAiããå
µåšãã¹ãã€ã¯ã¿ã³ãã¯ããéœåžãçºã«æ£åžããå°çåžæ°ãææã«é¥ããŸãã- ã«ã¬ã³ã»ãã³ã°ã¹ãã³
3  ãã£ãŒã«ãºãªããŒã»ã¢ããªãã£ãã¯ã¹ã¯ã9æ14æ¥ãåœé²é«çç ç©¶èšç»å±ïŒDARPAïŒãããååŠããã³çç©åŠçè
åšããæŠéå¡ãå®ãããã®æ°ãããã€ãªã·ã¹ãã ãœãªã¥ãŒã·ã§ã³ãéçºããç ç©¶æ©é¢ã®ããŒã ãçããå¥çŽãç²åŸãããšçºè¡šããŸããã
4  ãã©ã³ã¹ãã¥ãŒããã¹ãã®ç©¶æ¥µã®ç®æšã¯ã人éã®æèãããŠã³ããŒãã§ããç¡æ©ã»ææ©ãã¥ãŒããã€ãã®ãã©ãããã©ãŒã ãäœãããšã§ãããçµå±ã®ãšãããèäœã®å¯¿åœã¯éãããŠããã®ã ã
5  ãç§ã¯ã1998幎ã«ããã®ããã¹ã±ãŒã«ã®ã¯ã€ã€ãŒãæé·ãããæ¹æ³ãè§£æããæåã®äººç©ã®äžäººã§ããã
圌ã®è³ãå¶åŸ¡ããããŠã¹ãèŠãã°ããã
ãªãŒããŒæ°ã®ã泚å°åé»åæ©åšãã¯ããæå°éã®äŸµè¥²ãã§è³ãšäžäœåããå°ãªããšã1幎éã¯æ©èœãç¶ããããšããã§ã«èšŒæãããŠããã
6   ããªãŒããŒç ç©¶ã°ã«ãŒãã
ãªãŒããŒã°ã«ãŒãã¯ãããã¹ã±ãŒã«ã®ç§åŠæè¡ã«åºãçŠç¹ãåœãŠãŠãããæ°ããããææã®ç¬èªã®ç©ççç¹æ§ãå©çšããŠãçç©åŠãšå»åŠã®ç§åŠçå¢çãæŒãåºããŠããŸãã
çå¢çãæŒãåºããŠããŸãã
âãããã€ãªã€ã³ã¿ãŒãã§ã€ã¹

âæ°çŽ æ


